Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Midostaurin & Acute myeloid leukemia (AML) (FLT3 m)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Approval status

Midostaurin is approved by EMA for adults with newly diagnosed Acute myeloid leukemia (AML) (FLT3 m) as single-agent maintenance in patients achieving complete response after combination with standard daunorubicin and cytarabine induction chemotherapy.

Tzogani et al. 2019 ESMO Open 4(6): e000606

see also:
Acute myeloid leukemia (AML) (FLT3 m) & Drugs/Treatments
[Fms like tyrosine kinase 3 (FLT-3) inhibitors & Acute myeloid leukemia (AML) (FLT3 m)](brain://Nm2P-vod0EiFDNeK_BBLKQ/FmsLikeTyrosineKinase3Flt3InhibitorsAc…

References (Sources)

European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis
Tzogani et al. 2019 ESMO Open 4(6): e000606
Review

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!